Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on June 16, 2025. The filing addresses corporate governance matters regarding the company's upcoming Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on administrative changes to the Annual Meeting schedule and does not contain financial performance data.
Material Changes
- Meeting Date Change: The date of the 2025 Annual Meeting of Stockholders has been changed to August 1, 2025.
- Record Date: The record date for determining stockholders entitled to vote remains June 4, 2025, and has not been modified.
- Proxy Solicitation Deadline: To comply with universal proxy rules, stockholders intending to solicit proxies for director nominees other than the company's nominees must provide notice by June 26, 2025 (10 calendar days following this announcement).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors. The only operational detail provided is that the time and location of the meeting will be set forth in an amended definitive proxy statement to be filed with the SEC.
Investor Verification Checklist
- Verify the new meeting date of August 1, 2025, against the amended definitive proxy statement.
- Confirm the record date of June 4, 2025, to ensure eligibility to vote.
- Note the June 26, 2025 deadline for submitting notices for universal proxy solicitations.
- Check for the upcoming filing of the amended proxy statement for specific meeting time and location details.